Literature DB >> 23465547

Combining two serological assays optimises sensitivity and specificity for the identification of Streptococcus equi subsp. equi exposure.

Carl Robinson1, Karen F Steward, Nicola Potts, Colin Barker, Toni-ann Hammond, Karen Pierce, Eggert Gunnarsson, Vilhjálmur Svansson, Josh Slater, J Richard Newton, Andrew S Waller.   

Abstract

The detection of anti-Streptococcus equi antibodies in the blood serum of horses can assist with the identification of apparently healthy persistently infected carriers and the prevention of strangles outbreaks. The aim of the current study was to use genome sequencing data to develop an indirect enzyme linked immunosorbent assay (iELISA) that targets two S. equi-specific protein fragments. The sensitivity and specificity of the antigen A and antigen C iELISAs were compared to an SeM-based iELISA marketed by IDvet - diagnostic Vétérinaire (IDvet). Individually, each assay compromised specificity in order to achieve sufficient sensitivity (SeM iELISA had a sensitivity of 89.9%, but a specificity of only 77.0%) or sensitivity to achieve high specificity. However, combining the results of the antigen A and antigen C iELISAs permitted optimisation of both sensitivity (93.3%) and specificity (99.3%), providing a robust assay for the identification of horses exposed to S. equi.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Horses; Strangles; Streptococcus equi; iELISA

Mesh:

Substances:

Year:  2013        PMID: 23465547     DOI: 10.1016/j.tvjl.2013.01.033

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  8 in total

1.  Streptococcus equi Infections in Horses: Guidelines for Treatment, Control, and Prevention of Strangles-Revised Consensus Statement.

Authors:  A G Boyle; J F Timoney; J R Newton; M T Hines; A S Waller; B R Buchanan
Journal:  J Vet Intern Med       Date:  2018-02-09       Impact factor: 3.333

2.  Respiratory disease and sero-epidemiology of respiratory pathogens in the working horses of Ethiopia.

Authors:  G Laing; R Christley; A Stringer; N Aklilu; T Ashine; R Newton; A Radford; G Pinchbeck
Journal:  Equine Vet J       Date:  2018-05-17       Impact factor: 2.888

3.  Influence of penicillin treatment of horses with strangles on seropositivity to Streptococcus equi ssp. equi-specific antibodies.

Authors:  John Pringle; Emma Storm; Andrew Waller; Miia Riihimäki
Journal:  J Vet Intern Med       Date:  2019-11-26       Impact factor: 3.333

4.  SpeS: A Novel Superantigen and Its Potential as a Vaccine Adjuvant against Strangles.

Authors:  C Coral Dominguez-Medina; Nicola L Rash; Sylvain Robillard; Carl Robinson; Androulla Efstratiou; Karen Broughton; Julian Parkhill; Matthew T G Holden; Maria R Lopez-Alvarez; Romain Paillot; Andrew S Waller
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

5.  Markers of long term silent carriers of Streptococcus equi ssp. equi in horses.

Authors:  John Pringle; Monica Venner; Lisa Tscheschlok; Andrew S Waller; Miia Riihimäki
Journal:  J Vet Intern Med       Date:  2020-10-19       Impact factor: 3.333

6.  Streptococcus equi subspecies equi in horses in Israel: seroprevalence and strain types.

Authors:  S Tirosh-Levy; S E Blum; K F Steward; A S Waller; A Steinman
Journal:  Vet Rec Open       Date:  2016-08-16

7.  Decreased Clinical Severity of Strangles in Weanlings Associated with Restricted Seroconversion to Optimized Streptococcus equi ssp equi Assays.

Authors:  L Tscheschlok; M Venner; K Steward; R Böse; M Riihimäki; J Pringle
Journal:  J Vet Intern Med       Date:  2018-01       Impact factor: 3.333

8.  Genomic Dissection of an Icelandic Epidemic of Respiratory Disease in Horses and Associated Zoonotic Cases.

Authors:  Sigríður Björnsdóttir; Simon R Harris; Vilhjálmur Svansson; Eggert Gunnarsson; Ólöf G Sigurðardóttir; Kristina Gammeljord; Karen F Steward; J Richard Newton; Carl Robinson; Amelia R L Charbonneau; Julian Parkhill; Matthew T G Holden; Andrew S Waller
Journal:  mBio       Date:  2017-08-01       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.